In vitro steatosis hepatic cell model to compare the lipid-lowering effects of pomegranate peel polyphenols with several other plant polyphenols as well as its related cholesterol efflux mechanisms

• Published in: Toxicology reports 2014-01, Vol.1 (C), p.945-954
• Main Authors: Zhao, Wei, Li, Jianke, He, Xiaoye, Lv, Ou, Cheng, Yujiang, Liu, Run
• Format: Article
• Language: English
• Subjects: Hepatic cell; Lipid-lowering effects; Molecular mechanisms; Plant polyphenols; Pomegranate peel polyphenols (PPPs)
• ISSN: 2214-7500; 2214-7500
• DOI: 10.1016/j.toxrep.2014.10.013

This study was aimed to compare the relative activities of the purified pomegranate peels polyphenols (PPPs) with some other plant polyphenols including punicalagin, ellagic acid, gallic acid, phlorizin, and epigallocatechin gallate (EGCG) on the lipid metabolism regulation, and the cholesterol efflux mechanisms of PPPs and punicalagin were also investigated. In this paper, a convenient and accurate HL7702 steatosis hepatic cell model was applied to evaluate the lipid-lowering effects of the tested polyphenols. The results showed that PPPs possessed the strongest lipid-lowering effects. Prevention group (treated with polyphenols when establishing of steatosis model) was more effective than treatment group (treated with polyphenols after establishment of steatosis model). Punicalagin displayed the strongest lipid-lowering effects among all the tested components of pomegranate peel polyphenols. Moreover, PPPs and punicalagin (10, 20, 40 μg/mL) significantly increased the mRNA expression of LXRα (Liver X receptor alpha) and its target genes-ABCA1 (ATP-binding cassette transporter A1) in a dose-dependent manner in HL7702 steatosis hepatic cells. The high mRNA expression of LXRα and ABCA1, next to lovastatin, was observed in cells treated with 40 μg/mL of PPPs. These findings suggested that PPPs might have great potential in the clinic treatment of hyperlipemia.